title: Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
abstract: We investigated the activity of meropenem-clavulanic acid (MEM-CLA) against 68 Mycobacterium tuberculosis isolates. We included predominantly multi- and extensively drug-resistant tuberculosis (MDR/XDR-TB) isolates, since the activity of MEM-CLA for resistant isolates has previously not been studied extensively. Using Middlebrook 7H10 medium, all but four isolates showed an MIC distribution of 0.125 to 2 mg/liter for MEM-CLA, below the non-species-related breakpoint for MEM of 2 mg/liter defined by EUCAST. MEM-CLA is a potential treatment option for MDR/XDR-TB.
authors.affiliation: Unit of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden Department of Infectious Diseases, Karolinska University Hospital Solna, Stockholm, Sweden lina.davies-forsman@karolinska.se.
authors.forename: L
authors.identifier: http://orcid.org/0000-0001-8885-3320
authors.initials: L
authors.lastname: Davies Forsman
authors.affiliation: Department of Clinical Microbiology, Karolinska University Hospital, Solna, Sweden Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden.
authors.forename: C G
authors.initials: CG
authors.lastname: Giske
authors.affiliation: Unit of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden Department of Infectious Diseases, Karolinska University Hospital Solna, Stockholm, Sweden.
authors.forename: J
authors.initials: J
authors.lastname: Bruchfeld
authors.affiliation: Department of Medical Microbiology, Linköping University Hospital, Linköping, Sweden Department of Clinical Microbiology and Infectious Diseases, Kalmar County Hospital, Kalmar, Sweden.
authors.forename: T
authors.initials: T
authors.lastname: Schön
authors.affiliation: Unit of Highly Pathogenic Bacteria, Department of Microbiology, Public Health Agency of Sweden, Solna, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Juréen
authors.affiliation: Department of Clinical Microbiology, Karolinska University Hospital, Solna, Sweden Department of Microbiology, The University of the West Indies, Kingston, Jamaica.
authors.forename: K
authors.initials: K
authors.lastname: Ängeby
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology*; D019818:Clavulanic Acid / Q000494:pharmacology*; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D013845:Thienamycins / Q000494:pharmacology*; D018088:Tuberculosis, Multidrug-Resistant / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents; D013845:Thienamycins; D019818:Clavulanic Acid; D000077731:Meropenem
references.citation: Int J Antimicrob Agents. 2004 Apr;23(4):408-11
references.pmid: 15081094
references.citation: Scand J Infect Dis. 2001;33(6):466-9
references.pmid: 11450868
references.citation: Am Rev Respir Dis. 1968 Aug;98(2):295-6
references.pmid: 4299186
references.citation: Antimicrob Agents Chemother. 1983 Sep;24(3):429-31
references.pmid: 6416162
references.citation: Eur J Clin Microbiol. 1986 Aug;5(4):453-4
references.pmid: 3093225
references.citation: J Antimicrob Chemother. 1987 Jan;19(1):59-64
references.pmid: 3030999
references.citation: J Antimicrob Chemother. 1989 Sep;24 Suppl A:265-77
references.pmid: 2808212
references.citation: Chest. 1991 Apr;99(4):1025-6
references.pmid: 1901260
references.citation: Eur J Clin Pharmacol. 1992;42(1):3-9
references.pmid: 1541313
references.citation: Am Rev Respir Dis. 1992 Mar;145(3):657-60
references.pmid: 1546847
references.citation: Tuber Lung Dis. 1992 Jun;73(3):134-6
references.pmid: 1421344
references.citation: J Antimicrob Chemother. 1995 Jul;36 Suppl A:207-23
references.pmid: 8543496
references.citation: Antimicrob Agents Chemother. 1995 Dec;39(12):2620-4
references.pmid: 8592990
references.citation: J Antimicrob Chemother. 2013 Feb;68(2):366-9
references.pmid: 23070734
references.citation: Clin Infect Dis. 2013 Jan;56(2):236-44
references.pmid: 23074313
references.citation: Clin Infect Dis. 1998 Apr;26(4):874-7
references.pmid: 9564467
references.citation: Eur Respir J. 2013 Jun;41(6):1386-92
references.pmid: 22997218
references.citation: Antimicrob Agents Chemother. 2014 Dec;58(12):7557-9
references.pmid: 25246405
references.citation: Antimicrob Agents Chemother. 1998 Jun;42(6):1375-81
references.pmid: 9624479
references.citation: Antimicrob Agents Chemother. 1998 Jun;42(6):1524-6
references.pmid: 9624510
references.citation: J Antimicrob Chemother. 1998 Dec;42(6):735-40
references.pmid: 10052896
references.citation: Microbiology. 2005 Feb;151(Pt 2):521-32
references.pmid: 15699201
references.citation: Biochemistry. 2007 Oct 30;46(43):11998-2004
references.pmid: 17915954
references.citation: Biochemistry. 2008 May 13;47(19):5312-6
references.pmid: 18422342
references.citation: J Chemother. 2008 Jun;20(3):395-6
references.pmid: 18606602
references.citation: Science. 2009 Feb 27;323(5918):1215-8
references.pmid: 19251630
references.citation: J Antimicrob Chemother. 2009 Oct;64(4):786-93
references.pmid: 19633001
references.citation: Antimicrob Agents Chemother. 2011 Jun;55(6):2597-600
references.pmid: 21402832
references.citation: Pediatr Infect Dis J. 2011 Sep;30(9):812-3
references.pmid: 21378593
references.citation: Antimicrob Agents Chemother. 2012 Jun;56(6):3384-7
references.pmid: 22450968
references.citation: Int J Tuberc Lung Dis. 2012 Apr;16(4):558-60
references.pmid: 22325421
references.citation: Antimicrob Agents Chemother. 2004 Jun;48(6):2228-32
references.pmid: 15155226